Blinklab Limited · ASX:BB1
Blinklab — Investor Presentation (April 2024)
20 slides from Blinklab's investor presentation, Apr 4, 2024
Slide 1: Early diagnosis of autism using a breakthrough AI-powered smartphone platform
For personal use only Early diagnosis of autism Using a breakthrough AI-powered smartphone platform Current standard of care: April 2024, BlinkLab Ltd, Sydney The 126 Phillip diagn4stic process Street Level 5, NSW 2000, Dr. Henk-Jan Boele CEO 1
Slide 2: Disclaimer
Disclaimer For personal use only This presentation has been prepared by BlinkLab Limited (ACN 652 901 703) (BlinkLab or Company) and contains background information about BlinkLab’s current operations at the date of this presentation. The presentation is in summary form and does not purport to be al
Slide 3: Current Autism Market is $700B in the US alone
Current Autism Market is $700B in the US alone For personal use only ”The economic burden is significant and alarming” 1 ● Autism prevalence has grown to 2-4% among children2 ● Autism healthcare expenses world-wide are soaring3 - Costs for an autism diagnostic evaluation: $1,000 to $5,000. - Costs o
Slide 4: Source: ndis.gov.au
For personal use only Source: ndis.gov.au 4
Slide 5: Autism diagnosis is expensive, inaccurate, and too late
Autism diagnosis is expensive, inaccurate, and too late For personal use only Leading to poor developmental and clinical outcomes and high financial costs. Parental Autism Autism Diagnosis at Late observations screening diagnostic evaluation age 5-6 intervention Concerns arise By primary care Formal
Slide 6: BlinkLab's digital solution accelerates path to diagnosis
BlinkLab’s digital solution accelerates path to diagnosis For personal use only By bringing to market a smartphone platform for early and accurate autism diagnosis. Parental Digital Diagnostic Diagnosis at Early and personalized intervention observations screening evaluation age 2-3 and accurate mon
Slide 7: Our patented technology: neuroscience on a smartphone
Our patented technology: neuroscience on a smartphone For personal use only Minuscule facial reflexes, evoked by our app, generate a digital biomarker for autism. Smartphone-based Computer vision Scientifically-proven neurometric Facial features are tracked on the smartphone and evaluations convenie
Slide 8: How our AI technology detects autism and also ADHD
How our AI technology detects autism and also ADHD For personal use only BlinkLab precisely measures the alterations in sensory sensitivity in people with autism and ADHD. 8
Slide 9: BlinkLab is fully developed, field tested, and ready to use
BlinkLab is fully developed, field tested, and ready to use For personal use only Validated in >6,000 subjects tested globally, including people with limited access to healthcare. ● Remote testing Enables accessible and global diagnostics. ● Scalable solution Easily adaptable for clinical and divers
Slide 10: BlinkLab is collaborating with world-leading institutions
BlinkLab is collaborating with world-leading institutions Since our first product launched in 2022, we have established global partnerships with >30 academic and clinical institutes. For personal use only Prof. Samuel S. -H. Wang (Princeton University) “The BlinkLab app is easy to operate, substanti
Slide 11: Breakthrough data from large autism diagnostic study
Breakthrough data from large autism diagnostic study In our multi-center study in non-European cohort, we attained a sensitivity of 85% and specificity of 84% For personal use only Scores based on BlinkLab testing only. No additional questionnaires, such as ADOS of M-CHAT. Paper submitted for public
Slide 12: BlinkLab meets standard of care and outperforms FDA-approved digital peers
BlinkLab meets standard of care and outperforms FDA-approved digital peers For personal use only Sensitivity 85% 52% 71% Specificity 84% 19% 81% Smartphone-based Yes Yes No FDA approval Not yet De novo 510(k) We are leaders in the rapidly growing space of digital diagnostics and therapeutics. 12
Slide 13: First product to monitor the effect of therapy in real-time
First product to monitor the effect of therapy in real-time For personal use only Offers a path to even larger recurring revenues via subscription-based commercial models. Real-time Ritalin monitoring capability builds path to recurring revenue streams. 13
Slide 14: We are experts in science, tech and commercialization
We are experts in science, tech and commercialization For personal use only Our mission is to use neuroscience to improve the daily life of families with autism. Henk-Jan Boele, CEO Anton Uvarov, COO Bas Koekkoek, CSO Peter Boele, CTO Executive director MD, PhD, Neuroscientist and MBA, PhD, Biotechn
Slide 15: We are backed up by an expert advisory board
We are backed up by an expert advisory board For personal use only World leading scientists and commercial advisors. Company Chairman Company Director Company Director Scientific advisor Scientific advisor Scientific advisor Brian Leedman Jane Morgan Richard Hopkins Prof. Samuel Wang Prof. Chris De
Slide 16: R&D Pipeline
R&D Pipeline For personal use only Our pipeline of diagnostic products, relevant development state and regulatory pathway. Pre-clinical development Early clinical development Feasibility clinical studies Pivotal clinical studies Regulatory approval Post authorization Diagnostic: BlinkLab Dx 510(k)/C
Slide 17: Important milestones
Important milestones For personal use only News pipeline: Updates on regulatory studies on autism ánd ADHD, new partnerships, new opportunities Milestone Timeframe Start of activities for FDA registrational study in autism (appointment of CRO, selection and appointment of clinical 1H 2024 sited to d
Slide 18: Use of Funds: Regulatory approval and ready for launch
Use of Funds: Regulatory approval and ready for launch For personal use only FDA 510(k) and CE approval for BlinkLab as a diagnostic aid for autism spectrum disorder Full Subscription ($7,000,000) Allocation of funds Total % Expenses of the Public Offer $695,945 8.79% Software Improvement and Tech S
Slide 19: IPO metrics and capital structure
IPO metrics and capital structure For personal use only Full Subscription BOARD AND MANAGEMENT ($7,000,000) Shares Shares on issue at the date of the prospectus 64,150,003 Shares to be issued under the public offer 35,000,000 Total shares on issue on completion of the public offer 99,150,003 Options
Slide 20: Intellectual property
Intellectual property For personal use only Our patents prohibit other parties to conduct neurometric testing using mobile devices. BlinkLab has consistently prioritized the development We are represented by the US-based law firm, Our portfolio comprises patents filed both by Princeton and protectio